Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!

The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...

Gregory Korbel Biography and Net Worth

SVP of Aprea Therapeutics

Gregory A. Korbel., Ph.D. has served as our Chief Business Officer since March 2021, having previously served as Vice President, Business Development since July 2016. Dr. Korbel has more than 12 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Aprea Therapeutics, he was Director of Business Development and Operations at Novira Therapeutics, which was acquired in December 2015 by Johnson & Johnson, and served as Director of Research Operations subsequent to the acquisition. In addition to consulting for venture capital and biotechnology firms, he formerly served as Senior Scientist at Invtirogen/Life Technologies. Dr. Korbel received an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in Chemistry from Harvard University and a B.A. from Vanderbilt University.

How do I contact Gregory Alan Korbel?: The corporate mailing address for Dr. Korbel and other Aprea Therapeutics executives is 535 BOYLSTON STREET, BOSTON MA, 02116. Aprea Therapeutics can also be reached via phone at 617-463-9385 and via email at [email protected]. Learn More on Gregory Alan Korbel's contact information.
Has Gregory Alan Korbel been buying or selling shares of Aprea Therapeutics?: Gregory Alan Korbel has not been actively trading shares of Aprea Therapeutics during the last quarter. Most recently, Gregory Alan Korbel sold 1,375 shares of the business's stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $79.20, for a transaction totalling $108,900.00. Learn More on Gregory Alan Korbel's trading history.
Who are Aprea Therapeutics' active insiders?: Aprea Therapeutics' insider roster includes Lars Abrahmsen (SVP), Eyal Attar (SVP), and Gregory Korbel (SVP). Learn More on Aprea Therapeutics' active insiders.
Are insiders buying or selling shares of Aprea Therapeutics?: In the last year, Aprea Therapeutics insiders bought shares 4 times. They purchased a total of 13,938 shares worth more than $86,719.14. The most recent insider tranaction occured on March, 13th when CFO John P Hamill bought 1,010 shares worth more than $7,362.90. Insiders at Aprea Therapeutics own 20.9% of the company. Learn More about insider trades at Aprea Therapeutics.
Information on this page was last updated on 3/13/2024.

Gregory Alan Korbel Insider Trading History at Aprea Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/1/2021	Sell	1,375	$79.20	$108,900.00
9/20/2021	Sell	1,648	$99.40	$163,811.20

Gregory Alan Korbel Buying and Selling Activity at Aprea Therapeutics

Aprea Therapeutics Company Overview

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Today's Range

Now: $5.37

$5.14

$5.62

50 Day Range

MA: $6.44

$5.16

$8.46

2 Week Range

Now: $5.37

$2.78

$8.85

Volume

2,344 shs

Average Volume

29,867 shs

Market Capitalization

$29.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03